Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Gender differences in carbohydrate loading are related to energy intake.

Tarnopolsky MA, Zawada C, Richmond LB, Carter S, Shearer J, Graham T, Phillips SM.

J Appl Physiol (1985). 2001 Jul;91(1):225-30.

2.

Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.

Thompson J, Guichard SM, Cheshire PJ, Richmond LB, Poquette CA, Ragsdale ST, Webber B, Lorsbach R, Danks MK, Houghton PJ.

Cancer Chemother Pharmacol. 2001 Mar;47(3):211-21.

PMID:
11320664
3.

Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.

Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK, Stewart CF.

Clin Cancer Res. 2001 Feb;7(2):358-66.

4.

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Kirstein MN, Poquette CA, Tan M, Friedman HS, Brent TP.

Clin Cancer Res. 2000 Oct;6(10):4110-8.

5.

Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.

Thompson J, George EO, Poquette CA, Cheshire PJ, Richmond LB, de Graaf SS, Ma M, Stewart CF, Houghton PJ.

Clin Cancer Res. 1999 Nov;5(11):3617-31.

6.

Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.

Danks MK, Morton CL, Krull EJ, Cheshire PJ, Richmond LB, Naeve CW, Pawlik CA, Houghton PJ, Potter PM.

Clin Cancer Res. 1999 Apr;5(4):917-24.

7.

Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.

Pawlik CA, Houghton PJ, Stewart CF, Cheshire PJ, Richmond LB, Danks MK.

Clin Cancer Res. 1998 Aug;4(8):1995-2002.

8.

Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.

Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ.

Clin Cancer Res. 1998 Mar;4(3):743-53.

9.

Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.

Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF.

Clin Cancer Res. 1998 Feb;4(2):455-62.

10.

Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.

Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ.

J Natl Cancer Inst. 1998 Apr 1;90(7):505-11.

PMID:
9539245
11.

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, Stewart CF.

J Pharmacol Exp Ther. 1998 Jan;284(1):89-94.

PMID:
9435165
12.

Randomized trial of endovaginal ultrasound in preterm premature rupture of membranes.

Carlan SJ, Richmond LB, O'Brien WF.

Obstet Gynecol. 1997 Mar;89(3):458-61.

PMID:
9052605

Supplemental Content

Loading ...
Support Center